Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. - Wikidata - wikimedia - TriplyDB

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

http://www.wikidata.org/entity/Q33360724

about

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy Mammalian target of rapamycin: a central node of complex signaling cascades Updates of mTOR inhibitors mTOR inhibitors in advanced renal cell carcinoma CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin Overcoming cisplatin resistance by mTOR inhibitor in lung cancer.Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice Differentiating mTOR inhibitors in renal cell carcinoma Breast cancer chemoprevention: old and new approaches PI3K/PTEN signaling in angiogenesis and tumorigenesis Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2 Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779 Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors.Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial Novel targeted therapeutics for metastatic castration-resistant prostate cancer.The PIK3CA gene as a mutated target for cancer therapy.Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.Present and future evolution of advanced breast cancer therapy.Investigational approaches for mesothelioma.Exploiting novel molecular targets in gastrointestinal cancers.Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma.Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors Inhibition of mTOR in kidney cancer Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.The mTOR signaling pathway as a treatment target for intracranial neoplasms HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.Mammalian target of rapamycin and head and neck squamous cell carcinoma Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors.

P2860

Q21198871-DA9EF6F9-1BB6-484E-A759-CD536418957F Q24601702-774BF851-A313-4431-A4C2-F7E4E06D6089 Q24607170-7E79AC61-04B6-4B12-B68F-685E4789F85E Q24612127-340E9997-53C0-4853-8C44-8849F7CDF687 Q24672058-4FF96D08-DDB5-4044-B999-E11721878728 Q24806542-768E42B6-67DF-4795-A356-FDF565998A15 Q24811525-1CC592C7-25C7-4AA0-B73B-13B65E9F9310 Q24815638-6D57340E-AFA0-4431-9939-D4A5FB47126C Q26743390-84AB9A38-3CEC-4DAD-AFE8-4E5B5BF15074 Q26860172-61357D09-A0BE-4654-BF3A-256B10002EBF Q27693259-81F5627A-1815-4A78-8C91-EC296145E6C8 Q28383083-CC2F380A-8F4A-4EB7-8899-BF15EB8D937A Q30358123-A610E69B-E863-4972-B0B1-838E2933904A Q30430510-B03157F4-313F-4814-AA72-1033DB40C362 Q30438929-4DDF887D-6D24-447C-AF93-C8314AA10DFD Q33305157-22CEF5C0-15C0-43C7-A99B-5AC56B83B11C Q33383550-16974C2D-D90C-4622-9202-B221E452BBF1 Q33394687-E9024890-CE33-4B30-82CC-1F0BE7F6FFA4 Q33396953-2B065D20-FA62-4514-BF42-9DDABBAF095E Q33410022-240FDB0F-D553-44C5-8363-EEB95B943A80 Q33410691-96AA5D12-2E98-4D35-A31A-44E6E62143C4 Q33642278-268E9F57-D17E-4CDE-9C1C-18B2E74D0B30 Q33699378-5337DFA2-B43C-4235-9863-A9AE21DFC61B Q33985467-C34A0E83-502D-4907-AE66-F29FE6C83084 Q34129360-C37AE60D-8406-4A1A-B008-EB72C8CBC605 Q34181598-58850B20-66DF-49A5-AD2F-0B80DE59772A Q34274925-D6A4D4B3-2D45-4F79-919F-8657DAF2F8E2 Q34293068-FFB5DDB7-9385-4476-BD56-8976762D1BDC Q34382777-DADC3B50-506B-4EDF-B2E0-89C3F31A3F19 Q34536470-8E3774ED-9842-419F-BEAC-93F52E9C0543 Q34547487-0357745E-CF03-4A77-A20B-F2F8754EE493 Q34608329-3C8D6B03-D56E-4FFB-B9A7-47C7EB24D848 Q34767073-65E27761-0E71-473F-AE5B-0AA6466312CC Q34886859-0E980B0F-D26F-4E3C-8271-A8FD203AF5F8 Q34974436-D550C3D4-114A-44B5-B3EC-A1047CAD0EC2 Q35027222-91477C5A-9A65-4A14-B145-4E0D73AEB838 Q35069652-CFB807EE-3AFB-4B39-B5BC-E83FA8B065CE Q35085333-EC5FA293-0F77-4690-BFA9-40C57ECABA1C Q35091507-A4D57B3C-83DE-4E67-80F1-3D889B452291 Q35112340-FF1936A8-9032-4302-A15A-DA6726095126

P2860

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

http://www.wikidata.org/entity/Q33360724

description

2004 nî lūn-bûn

@nan

2004 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Safety and pharmacokinetics of ...... itor, in patients with cancer.

@ast

Safety and pharmacokinetics of ...... itor, in patients with cancer.

@en

type

label

Safety and pharmacokinetics of ...... itor, in patients with cancer.

@ast

Safety and pharmacokinetics of ...... itor, in patients with cancer.

@en

prefLabel

Safety and pharmacokinetics of ...... itor, in patients with cancer.

@ast

Safety and pharmacokinetics of ...... itor, in patients with cancer.

@en

P1433

Q33360724-58E5F9F2-9C0F-44A5-8E9F-D8B1F3783534

P1476

Q33360724-B7F47D68-0CDC-4972-935B-D39A82594E1E

P2093

Q33360724-0F6101FB-7CA7-4C65-BC18-00B58F9483C9

Q33360724-4194510A-8794-4AF4-A374-1BCE13AF0B88

Q33360724-4666AFA2-0124-4A16-9F72-2719C0C8F1B3

Q33360724-55745559-9CF2-4511-A168-D5614868F9A3

Q33360724-7248FE09-2B3A-4E19-A737-3E5A27D105CE

Q33360724-AAE4BDF9-D4A4-4983-9064-2B63082C3D88

Q33360724-C8014460-7676-4478-8303-7E8CC676FD12

Q33360724-CE08B9E2-DD19-46BB-AE5C-0AE70A4AA13B

Q33360724-F1026E74-452A-4C37-ADB2-1DC74C6330E6

P304

Q33360724-60BCC418-8222-4518-A234-6ACD596B2B18

P31

Q33360724-1999C2F8-54DF-422D-8B59-D3A8815F937B

P356

Q33360724-4B89EA10-7354-4858-82C3-98B4DFEB8FE8

P407

Q33360724-9C9558D9-934E-4FAE-93CA-94ADA1007478

P433

Q33360724-6DE5A832-0737-4584-A50F-BFF64942C216

P478

Q33360724-CF052109-1089-4D52-A2F0-0422C3380BDA

P50

Q33360724-B4EB986A-7AD2-4D01-87D9-454CE4A031AE

P577

Q33360724-7698D211-AC75-4E0B-B455-128809D9EDBE

P698

Q33360724-1E4FB91F-30B1-4A7E-B765-151CFBFCED00

P356

JCO.2004.08.116

P1433

Journal of Clinical Oncology

P1476

Safety and pharmacokinetics of ...... itor, in patients with cancer.

@en

P2093

Axel Hanauske

http://www.w3.org/2001/XMLSchema#string

Cathie Leister

http://www.w3.org/2001/XMLSchema#string

Eric Materman

http://www.w3.org/2001/XMLSchema#string

Eric Raymond

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Armand

http://www.w3.org/2001/XMLSchema#string

Joan Korth-Bradley

http://www.w3.org/2001/XMLSchema#string

Joseph Boni

http://www.w3.org/2001/XMLSchema#string

Jérôme Alexandre

http://www.w3.org/2001/XMLSchema#string

Karina Vera

http://www.w3.org/2001/XMLSchema#string

P304

2336-2347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2004.08.116

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Sandrine Faivre

P577

2004-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15136596

http://www.w3.org/2001/XMLSchema#string